Literature DB >> 25828104

Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis.

Bing H Wang1, Thomas G von Lueder2, Andrew R Kompa3, Li Huang1, Randy Webb4, Pierre Jordaan5, Dan Atar6, Henry Krum7.   

Abstract

Entities:  

Keywords:  ARNi; Angiotensin; LCZ696; Natriuretic peptide; Neutral endopeptidase; Renal fibrosis

Mesh：

Substances：

Year:  2015        PMID： 25828104     DOI： 10.1016/j.ijcard.2015.03.116

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  15 in total

1.  LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Authors:  Wanghui Jing; Nosratola D Vaziri; Ane Nunes; Yasunori Suematsu; Ted Farzaneh; Mahyar Khazaeli; Hamid Moradi
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

Authors:  Giuseppe Mulè; Alessandra Sorce; Emilio Nardi; Giulio Geraci; Santina Cottone
Journal:  Intern Emerg Med       Date:  2019-07-15       Impact factor: 3.397

3.  The burden of heart failure in the general population: a clearer and more concerning picture.

Authors:  Thomas G von Lueder; Stefan Agewall
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

4.  Neurohormonal Blockade in Heart Failure.

Authors:  Thomas G von Lueder; Dipak Kotecha; Dan Atar; Ingrid Hopper
Journal:  Card Fail Rev       Date:  2017-04

Review 5.  Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature.

Authors:  Feby Savira; Ruth Magaye; Danny Liew; Christopher Reid; Darren J Kelly; Andrew R Kompa; S Jeson Sangaralingham; John C Burnett; David Kaye; Bing H Wang
Journal:  Br J Pharmacol       Date:  2020-05-13       Impact factor: 8.739

6.  Study of endothelial function and vascular stiffness in patients affected by dilated cardiomyopathy on treatment with sacubitril/valsartan.

Authors:  Ludovica Amore; Fabio Alghisi; Edoardo Pancaldi; Greta Pascariello; Angelica Cersosimo; Giuliana Cimino; Nicola Bernardi; Emiliano Calvi; Carlo Mario Lombardi; Edoardo Sciatti; Enrico Vizzardi; Marco Metra
Journal:  Am J Cardiovasc Dis       Date:  2022-06-15

Review 7.  New medical therapies for heart failure.

Authors:  Thomas G von Lueder; Henry Krum
Journal:  Nat Rev Cardiol       Date:  2015-09-29       Impact factor: 32.419

Review 8.  From ARB to ARNI in Cardiovascular Control.

Authors:  Estrellita Uijl; Lodi C W Roksnoer; Ewout J Hoorn; A H Jan Danser
Journal:  Curr Hypertens Rep       Date:  2016-12       Impact factor: 5.369

9.  Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.

Authors:  Takunori Seki; Kenichi Goto; Yasuo Kansui; Toshio Ohtsubo; Kiyoshi Matsumura; Takanari Kitazono
Journal:  J Am Heart Assoc       Date:  2017-10-17       Impact factor: 5.501

10.  Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  Zhanna Kobalava; Yulia Kotovskaya; Oleg Averkov; Elena Pavlikova; Valentine Moiseev; Diego Albrecht; Priya Chandra; Surya Ayalasomayajula; Margaret F Prescott; Parasar Pal; Thomas H Langenickel; Pierre Jordaan; Iris Rajman
Journal:  Cardiovasc Ther       Date:  2016-08       Impact factor: 3.023
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.